Tuesday , January 23 2018
Home / Letter From The Editor (page 40)

Letter From The Editor

Letter from the Editor, #750: ACO Update

Two years ago the Affordable Care Act brought about the beginning of ACO’s (accountable care organizations). These organizations were created to bring quality of care into play for patients and to reward the best care providers with financial incentives. CMS wanted to prove the value of these ACO’s and so …

Read More »

Editor’s Note, DCMS #209

When we were kids, we used to play a game called Red Light/Green Light, and the goal was to sneak up on the "it" person without them catching your moves. In this week’s Homerun Slides series, we bring you a way to use this game to help your patients get …

Read More »

Letter from the Editor, #749

This week we find that a lot of information is coming out the EASD meeting in Vienna, and much of it has to do with the use of pump therapy in patient care. There is also a great article that dispels any concerns you may have about starting your patients …

Read More »

Editor’s Note, DCMS #208

The FDA works really hard these days to come up with new brand names that will lessen the chance of drug choice confusion. Often times we wonder how they can come up with these names and what meaning they have. With this in mind, this week’s Diabetes Disaster Averted points …

Read More »

Letter from the Editor, #748

For the past 18 months we have been providing you with a monthly newsletter with special features focused on GLP-1 analogs. These newsletters have provided information beginning with the first discovery of GLP-1 and GIP in the body and how they worked to control glucose levels, and have included practice …

Read More »

Editor’s Note, DCMS #207

In 1969, the group Santana first recorded the song "Evil Ways" with these lines, "You’ve got to change your evil ways, baby … You’ve got to change, baby, And every word that I say is true…." It seems that when it comes to the treatment of type 2 diabetes, we actually …

Read More »

Letter from the Editor, #747:

This was a busy week in the GLP-1 arena. An FDA advisory panel last week overwhelmingly recommended approval of Novo Nordisk’s latest weight-loss drug, Saxenda. This medication, which is liraglutide 3 mg, was recommended as an adjunct to diet and exercise in adults with a BMI of 30 or more, …

Read More »

Editor’s Note, DCMS #206

When Al Mann first said he was going to develop an inhaled insulin, many thought he was beating a dead horse after the collective experiences with Exubera. They forgot that Al had already built the most successful pump company of all times, and that he did not like to fail. …

Read More »